Beth A. Kurt
Expertise in
4
conditions

Dr. Beth A. Kurt

Pediatric Hematology Oncology
1105 Sixth Street, 
Traverse City, MI 
On Staff At
Accepting New Patients
25 Years of Experience
Expertise in
4
conditions
1105 Sixth Street, 
Traverse City, MI 

Overview

Beth Kurt is a Pediatric Hematologist Oncology provider in Traverse City, Michigan. Dr. Kurt has been practicing medicine for over 25 years is highly rated in 4 conditions, according to our data. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Hereditary Spherocytosis, Congenital Athymia, and Febrile Neutropenia. Dr. Kurt is currently accepting new patients.

Her clinical research consists of co-authoring 7 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

Michigan State University College Of Human Medicine, 2001

Residency

Grand Rapids Medical Education Partners, Internal Medicine & Pediatrics

Specialties

Pediatric Hematology Oncology

Licenses

Pediatric Hematology-Oncology in MI

Board Certifications

American Board Of Pediatrics, Pediatric Hematology-Oncology - 2009
American Board Of Internal Medicine, Internal Medicine - 2005
American Board Of Pediatrics, Pediatrics - 2005

Fellowships

University of Tennessee Health Science Center College of Medicine, Pediatric Hematology-Oncology, 2008

Hospital Affiliations

Munson Medical Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Upper Peninsula Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
View 8 Less Insurance Carriers -

Locations

Helen DeVos Children's Hospital Pediatric Hematology and Oncology Clinic
1105 Sixth Street, Traverse City, MI 49684
Other Locations
Helen DeVos Children's Hospital Hematology and Oncology
100 Michigan Street Northeast, Floor 10, Grand Rapids, MI 49503

Additional Areas of Focus

Dr. Kurt has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess Its Efficacy, Safety, Impact on Quality of Life, and Long-term Outcome in Pediatric Patients With Primary Hemophagocytic Lymphohistiocytosis
An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess Its Efficacy, Safety, Impact on Quality of Life, and Long-term Outcome in Pediatric Patients With Primary Hemophagocytic Lymphohistiocytosis
Enrollment Status: Completed
Publish Date: March 12, 2024
Intervention Type: Drug
Study Drug: Emapalumab
Study Phase: Phase 3
A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody
A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody
Enrollment Status: Completed
Publish Date: June 28, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
View 1 Less Clinical Trial

7 Total Publications

Allogeneic hematopoietic cell transplantation rescues congenital red cell aplasia in H syndrome due to SLC29A3 mutations.
Allogeneic hematopoietic cell transplantation rescues congenital red cell aplasia in H syndrome due to SLC29A3 mutations.
Journal: Haematologica
Published: April 22, 2025
Similar Doctors
Matthew G. Pridgeon
Expertise in
4
conditions
Dr. Matthew G. Pridgeon
Pediatric Hematology Oncology
Expertise in
4
conditions
Dr. Matthew G. Pridgeon
Pediatric Hematology Oncology

Helen DeVos Children's Hospital Pediatric Hematology And Oncology Clinic

1105 Sixth Street, 
Traverse City, MI 
 (192.0 miles away)
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Matthew Pridgeon is a Pediatric Hematologist Oncology provider in Traverse City, Michigan. Dr. Pridgeon has been practicing medicine for over 16 years is highly rated in 4 conditions, according to our data. His top areas of expertise are Sickle Cell Disease, Hereditary Spherocytosis, Hemoglobin SC Disease, and Acute Lymphoblastic Leukemia (ALL). Dr. Pridgeon is currently accepting new patients.

David J. Hoogstra
Expertise in
1
conditions
Dr. David J. Hoogstra
Pediatric Hematology Oncology
Expertise in
1
conditions
Dr. David J. Hoogstra
Pediatric Hematology Oncology

Helen DeVos Children's Hospital Pediatric Hematology And Oncology Clinic

1105 Sixth Street, 
Traverse City, MI 
 (192.0 miles away)
Experience:
10+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Hoogstra is a Pediatric Hematologist Oncology provider in Traverse City, Michigan. Dr. Hoogstra has been practicing medicine for over 10 years is highly rated in 1 condition, according to our data. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Febrile Neutropenia, Malignant Peripheral Nerve Sheath Tumor, and Cerebral Ventricle Cancer. Dr. Hoogstra is currently accepting new patients.

Andrew S. Cole
Expertise in
0
conditions
Dr. Andrew S. Cole
Physiatry | Pediatric Hematology Oncology
Expertise in
0
conditions
Dr. Andrew S. Cole
Physiatry | Pediatric Hematology Oncology

Kalkaska Medical Associates Specialty Clinic

419 South Coral Street, 
Kalkaska, MI 
 (197.9 miles away)
231-258-7749
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Andrew Cole is a Physiatrist and a Pediatric Hematologist Oncology provider in Kalkaska, Michigan. Dr. Cole has been practicing medicine for over 17 years. His top areas of expertise are Post Polio Syndrome, Spasticity, Myositis, and Macrophagic Myofasciitis. Dr. Cole is currently accepting new patients.

Frequently Asked Questions about Dr. Beth A. Kurt

How do I make an appointment with Dr. Beth A. Kurt?

You can book an appointment with Dr. Beth A. Kurt by calling their office at 616-267-1925. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Beth A. Kurt a top-rated expert for Acute Lymphoblastic Leukemia (ALL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Beth A. Kurt is classified as an Advanced expert for Acute Lymphoblastic Leukemia (ALL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Beth A. Kurt specialize in?

While Dr. Beth A. Kurt is a Pediatric Hematology Oncology, they have specific expertise in Acute Lymphoblastic Leukemia (ALL), Hereditary Spherocytosis, and Congenital Athymia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatric Hematology Oncology.

Does Dr. Beth A. Kurt participate in research or clinical trials?

Yes. Dr. Beth A. Kurt has published 7 articles and abstracts on conditions like Acute Lymphoblastic Leukemia (ALL). You can view a list of Dr. Beth A. Kurt's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Beth A. Kurt accept my insurance?

Dr. Beth A. Kurt accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 616-267-1925 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kurt's expertise for a condition
ConditionClose
      View All 56 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile